Biotechnology News

GERMANTOWN, Md., Feb. 08, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company developing novel treatments for nervous system diseases, today announced that Richard...

- Net Revenue increased 2.5% for the fourth quarter and 9% for the full year 2017- - Conference call at 8:30 a.m. ET on February 8, 2018 - EAST RUTHERFORD, N.J., Feb. 08, 2018 (GLOBE NEWSWIRE)...

The scientific results from intratumoral injections with Liproca® Depot as confirmed by Magnetic Resonance Imaging and Spectroscopy, have been accepted for presentation at the International Society...

Ellen har idag tecknat av tal med MedicaNatumin om samarbete om utveckling av en ny intimhälsoprodukt för både kvinnor och män. Produkten kommer att innehålla MedicaNatumins patenterade teknologi....

Stockholm, 2018-02-08 08:00 CET (GLOBE NEWSWIRE) -- PledOx® is a drug candidate in development for the prevention of chemotherapy induced peripheral neuropathy in colorectal cancer patients. The...

Stockholm, 2018-02-08 08:00 CET (GLOBE NEWSWIRE) -- PledOx® är en läkemedelskandidat med potential att förebygga cellgiftsinducerade perifera nervskador hos patienter som behandlas för tjock-...

LA JOLLA, Calif., Feb. 07, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange...

NEW YORK and LONDON, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX) (“Akari” or “the Company”), a biopharmaceutical company focused on the development and commercialization...

Newly Released Second Phase 3 Study Data for Durasert Three-Year Treatment for Posterior Segment Uveitis Shows Positive Efficacy and Safety Profile Maintained at 12 Months      Awaiting FDA...

Highly Significant Difference Between Durasert and Sham in Prevention of Uveitis Recurrence at 12 Months Fiscal Q2 2018 Results Conference Call Scheduled for Today at 4:30 p.m.ET WATERTOWN,...